News

• Adjusted Group revenues increase by 6% to €4.3 billion, with all three segments – Specialty, Consumer Healthcare and Generics – growing in 2025;
  adjusted constant-currency EBITDA improves by 8% to €961 million
  
  
• Revenues by STADA’s Specialty segment exceed €1 billion for the first time in 2025 on 17% growth, driven by biosimilars and innovative medicines
  
  
• STADA CEO Peter Goldschmidt: “All our regions ̵  Western Europe, Central & Eastern Europe, Germany and Middle East & Asia  ̵  are contributing nicely to our growth. Key drivers for our above-industry growth were several great launches across all our three segments. On top of this, we in-licensed in 2025 alone 110 new products securing an even stronger pipeline for a successful future.”

Bad Vilbel, Germany – 18 March 2026 – STADA in 2025 again demonstrated the success of its three-segment strategy, that provides patients and healthcare professionals with a broad range of medicines and healthcare products across Consumer Healthcare, Generics and Specialty, including innovative medicines.

Adjusted, constant-currency (adj. cc) Group revenues increased by 6% to €4.3 billion in the financial year ended 31 December 2025. Group earnings before interest, tax, depreciation and amortization (EBITDA)  ̵  adjusted for special items and at constant exchange rates  ̵  improved by 8% to €961 million.

“All our regions  ̵  Western Europe, Central & Eastern Europe, Germany and Middle East & Asia  ̵  are contributing nicely to our growth. Key drivers for our above-industry growth were several great launches across all our three segments. On top of this, we in-licensed in 2025 alone 110 new products securing an even stronger pipeline for a successful future,” commented STADA CEO Peter Goldschmidt.


Biosimilars and Innovative Medicines Growth Takes Specialty over €1 billion

Specialty revenues climbed by 17% on an adjusted, constant-currency basis, now accounting for almost one quarter of Group revenues. The segment thus maintained its double-digit growth trajectory of recent years.

Building on proven partnerships with developers across Europe and China, in combination with a strong marketing and sales platform across all European markets, biosimilars sales advanced in double digits. Key drivers included the continued growth of Uzpruvo (ustekinumab), which captured top positions in all of the more than 20 markets where the brand has been launched, as well as further growth from the existing biosimilars portfolio across broad range of therapeutics areas such as bone health, immunology and oncology. Five biosimilar launches are scheduled during 2026, including golimumab and tocilizumab, as STADA builds on its position as a biosimilars leader in Europe with a broad portfolio consisting of 11 approved products, along with geographic presence and patient outreach in Europe that few competitors can match.

Innovative medicines made significant progress, expanding patient access to best-in-class treatments for serious conditions in nephrology and neurology.

High double-digit growth for Kinpeygo was driven by successful expansion of the label, allowing for use in a larger cohort of patients with the rare kidney disease IgAN. Following launches in 19 European countries to date, Kinpeygo’s uptake was further accelerated by endorsement in the KDIGO clinical treatment guidelines as well as real-world data on safety and efficacy. Launches in additional markets are planned for 2026 and beyond.

In neurology, launches of the Lecigon intestinal infusion pump in additional countries including France and the UK expanded access for people living with advanced Parkinson’s disease. After enjoying broad success in Europe with apomorphine, a subcutaneous infusion device for treatment of moderate-to-severe Parkinson’s patients, STADA has launched the therapy, under the brand name ONAPGO, in the sizable US market with its partner Supernus. In addition, STADA during 2025 expanded its Specialty oncology portfolio by launching nilotinib and paclitaxel albumin.

Rivaroxaban leads above-market Generics growth

2025 Generics revenues advanced by 5% (adj cc) as the segment continued to outperform the market in Europe. Generics growth was driven in large part by a successful rivaroxaban launch achieved through a strong intellectual-property position. Several successful launches and commercial synergy enhanced STADA’s top-three retail generics market ranking in countries like Germany, Italy, Spain, Belgium, Ireland, the Nordics, Serbia and Switzerland.

Performance in Generics was further fueled by cardiovascular medicines, in particular apixaban, dabigatran and ticagrelor, as well as from several statins. STADA also benefited from filling in gaps in local Generics portfolios, such as with enoxaparin in Belgium, or the Proxor (beclomethasone/formoterol) inhaler in the UK.

Consumer Healthcare grows with local hero brands despite soft cough/cold season

Despite a relatively low incidence of coughs and colds in key markets, the Consumer Healthcare segment delivered a solid performance in 2025 with 2% (adj cc) revenues growth. Outside the cough & cold category, STADA delivered mid-single-digit growth, based on continued strong performance of its industry-leading number of top-ranked brands across various country-categories such as: Nizoral, Levomecol and Cetraben in dermatology; Elotrans and Protectis in gastrointestinal; and Eunova, Walmark and Natures Aid in vitamins, minerals and supplements. The segment continued to make progress with several significant launches and line extensions including extensions to the Nizoral scalp-care brand, including Nizoral Care Conditioner and Nizoral Cream. STADA’s top brand in the UK, Zoflora, benefitted from line extensions in the home hygiene and disinfectants sectors.

Reflecting and anticipating consumer trends, STADA nearly doubled its eCommerce sales between 2022 and 2025, with more than half of the Group’s media budget allocated to digital channels. STADA continues to accelerate eCommerce growth by expanding geographically and adopting an omnichannel approach to engage consumers on platforms like Google, TikTok and Instagram, as well as making targeted use of AI technologies.

Evaluating acquisition targets worldwide

“To drive further Consumer Healthcare growth,” revealed Goldschmidt, “we are actively evaluating acquisition targets around the world to enhance our broad healthcare platform, on top of our strong internal pipeline. At the same time, we continue to capitalize on opportunities to expand our brand portfolio in the fastest-growing categories such as dermatology, preventive health and wellness.”

Strong build-out of future pipeline

“Our oncology pipeline is highly promising, containing molecules such as enzalutamide and ruxolitinib, and we have apixaban and edoxaban to complement our ongoing launch of rivaroxaban in the cardiovascular category.”

“Our biosimilar partnerships are set to deliver imminent entry into limited-competition markets such as golimumab and tocilizumab, building on our denosumab launch in Europe at the end of 2025,” Goldschmidt continued. “Through the 110 business development and licensing (BD&L) deals we signed in 2025, on top of our extensive development and licensing partnership network, we have built a highly-promising pipeline for years to come.”

“We are fully prepared with a well-stocked development pipeline and strategy to address the GLP-1 loss-of-exclusivity opportunities in both diabetes and weight-loss, targeting blockbuster brands such as semaglutide-based Ozempic and Wegovy, and liragutide-based Saxenda and Victoza. On top of this, the SGLT-2 inhibitor empagliflozin is a key pipeline asset in diabetes.”

Culture Drives Performance

Highlighting STADA’s recent re-certification as a Top Employer Europe, as well as 88% employee participation in the latest employee survey with four in five proud to work for STADA, far outperforming industry norms, Goldschmidt concluded: “Beyond all operations and pipeline opportunities, what keeps STADA performing ahead of the market is our unique One STADA spirit and growth culture. The outstanding dedication of our almost 12,000 employees around the world, more than half of which work in our TechOps team ensuring reliable supplies of medicines to patients, is the foundation of our continued growth journey and our devotion to ‘Caring for People’s Health as a Trusted Partner’.”

About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in over 100 countries. In financial year 2025, STADA achieved group sales of € 4,296 million and adjusted constant-currency earnings before interest, taxes, depreciation and amortization (adj. cc EBITDA) of € 961 million. As of 31 December 2025, STADA employed 11,749 people worldwide.

Additional information for journalists
STADA Arzneimittel AG - Media Relations
Stadastrasse 2-18, 61118 Bad Vilbel - Germany
Phone: +49 (0) 6101 603-165
E-Mail: [email protected]
Or visit us via our website at https://www.stada.com/media/newsroom
Follow @stadaGroup on LinkedIn

Additional information for capital market participants
STADA Arzneimittel AG - Investor & Creditor Relations
Stadastrasse 2-18, 61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-4689
Fax: +49 (0) 6101 603-215
E-mail: [email protected]